Vascular Endothelial Growth Factor B VEGF Related Factor or VEGFB Pipeline Review, H1 2018 [Report Updated: 17042018] Prices from USD $3500

15:52 EDT 4 Aug 2018 | BioPortfolio Reports

Vascular Endothelial Growth Factor B VEGF Related Factor or VEGFB Pipeline Review, H1 2018


Summary


Vascular Endothelial Growth Factor B VEGF Related Factor or VEGFB Vascular endothelial growth factor B also known as VEGFB is a protein encoded by the VEGFB gene. It regulates the formation of blood vessels and is involved in endothelial cell physiology. It is a ligand for VEGFR1 vascular endothelial growth factor receptor 1 and NRP1 neuropilin1.


Vascular Endothelial Growth Factor B VEGF Related Factor or VEGFB pipeline Target constitutes close to 8 molecules. The molecules developed by companies in PreRegistration, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 5 respectively. Report covers products from therapy areas Metabolic Disorders, Ophthalmology and Oncology which include indications Wet Neovascular / Exudative Macular Degeneration, Diabetic Macular Edema, Diabetic Nephropathy, Diabetic Retinopathy, Choroidal Neovascularization, Lipid Disorders, Neovascular Glaucoma, NonProliferative Diabetic Retinopathy NPDR, Optic Neuropathy, Retinal Vein Occlusion and Retinopathy.


The latest report Vascular Endothelial Growth Factor B Pipeline Review, H1 2018, outlays comprehensive information on the Vascular Endothelial Growth Factor B VEGF Related Factor or VEGFB targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


It also reviews key players involved in Vascular Endothelial Growth Factor B VEGF Related Factor or VEGFB targeted therapeutics development with respective active and dormant or discontinued projects.


The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B VEGF Related Factor or VEGFB

The report reviews Vascular Endothelial Growth Factor B VEGF Related Factor or VEGFB targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Vascular Endothelial Growth Factor B VEGF Related Factor or VEGFB targeted therapeutics and enlists all their major and minor projects

The report assesses Vascular Endothelial Growth Factor B VEGF Related Factor or VEGFB targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Vascular Endothelial Growth Factor B VEGF Related Factor or VEGFB targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B VEGF Related Factor or VEGFB

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B VEGF Related Factor or VEGFB development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

More From BioPortfolio on "Vascular Endothelial Growth Factor B VEGF Related Factor or VEGFB Pipeline Review, H1 2018 [Report Updated: 17042018] Prices from USD $3500"